ClinicalTrials.Veeva

Menu

Ultra-low Dose Contrast for Endovascular Procedures (ULTRA-LOW)

A

Attikon University Hospital

Status

Active, not recruiting

Conditions

Renal Impairment
Limb Ischemia, Critical

Treatments

Procedure: Infrainguinal peripheral endovascular revascularization

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The purpose of this protocol is to study the safety and feasibility of using ultra-low dose iodinated contrast agent for infrainguinal endovascular revascularization procedures in patients with chronic limb-threatening lower limb ischemia (CLTI) and impaired renal function, in the new angiography suite of our department.

Full description

Prospective, single-center observational study of patients with CLTI and renal failure but not on dialysis (eGFR <60ml/minute/1.73m2, renal disease stages 2-4), who are scheduled to undergo endovascular revascularization procedures of the lower limb arteries. The procedures will be performed on the new angiograph of the interventional radiology unit (Philips Azurion 7 b20/15 biplane) and the contrast administration protocol will include 1:9 or 2:9 dilutions of iso-osmotic iodinated contrast agent (Visipaque 320mg/ml) with saline, with the aim of administering the minimum possible amount for the safe and effective performance of the procedure (As Low As Possible; ALARA).

Enrollment

18 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • CLTI
  • Prescheduled infrainguinal revascularization procedure
  • Renal disease stage 2-4 (eGFR <60ml/minute/1.73m2)
  • Adequate pre- and post-procedural hydration protocol

Exclusion criteria

  • Inadequate pre- and post-procedural hydration protocol
  • End-stage renal disease/ dialysis
  • eGFR >60ml/minute/1.73m2)
  • Endovascular treatment of Iliac artery steno-oclussive disease
  • Allergy to contrast media

Trial design

18 participants in 1 patient group

Study cohort
Description:
Patients with renal disease stages 2-4, scheduled to undergo infrainguinal endovascular procedures due to CLTI, using ultra-low dose of iodine contrast media.
Treatment:
Procedure: Infrainguinal peripheral endovascular revascularization

Trial contacts and locations

1

Loading...

Central trial contact

Stavros C Spiliopoulos, MD, PhD; Vasiliki Zygouri, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems